RESUMO
For decades, vaccination with the 23-valent polysaccharide pneumococcal vaccine (PPV23) has been available for risk groups aged ⩾2 years to prevent invasive pneumococcal disease (IPD). Recently, a 13-valent pneumococcal conjugated vaccine (PCV13) has been licensed for use in all age groups. PCV13 may induce better protection than PPV23 because of different immunogenic properties. This called for a revision of vaccine recommendations for risk groups. We therefore reviewed literature on risk groups for IPD, and effectiveness and safety of pneumococcal vaccines and supplemented that with information from public health institutes, expert consultations and data on IPD epidemiology. We included 187 articles. We discuss the implications of the heterogenic vulnerability for IPD within and between risk groups, large indirect effects of childhood immunization, and limited knowledge on additional clinical benefits of PCV13 in combination with PPV23 for the Norwegian recommendations. These are now step-wise and consider the need for vaccination, choice of pneumococcal vaccines, and re-vaccination interval by risk group.
Assuntos
Infecções Pneumocócicas/imunologia , Infecções Pneumocócicas/prevenção & controle , Vacinas Pneumocócicas/imunologia , Adolescente , Adulto , Criança , Pré-Escolar , Política de Saúde , Humanos , Noruega/epidemiologia , Infecções Pneumocócicas/epidemiologia , Vacinas ConjugadasRESUMO
Pathogen adaptation has been proposed to contribute to the resurgence of pertussis. A striking recent example is the emergence of isolates deficient in the vaccine component pertactin (Prn). This study explores the emergence of such Prn-deficient isolates in six European countries. During 2007 to 2009, 0/83 isolates from the Netherlands, 0/18 from the United Kingdom, 0/17 Finland, 0/23 Denmark, 4/99 Sweden and 5/20 from Norway of the isolates collected were Prn-deficient. In the Netherlands and Sweden, respectively 4/146 and 1/8 were observed in a later period (201012). The Prn-deficient isolates were genetically diverse and different mutations were found to inactivate the prn gene. These are indications that Prn-deficiency is subject to positive selective pressure. We hypothesise that the switch from whole cell to acellular pertussis vaccines has affected the balance between 'costs and benefits' of Prn production by Bordetella pertussis to the extent that isolates that do not produce Prn are able to expand. The absence of Prn-deficient isolates in some countries may point to ways to prevent or delay the spread of Prn-deficient strains. In order to substantiate this hypothesis, trends in the European B. pertussis population should be monitored continuously.
Assuntos
Proteínas da Membrana Bacteriana Externa/análise , Proteínas da Membrana Bacteriana Externa/genética , Bordetella pertussis/isolamento & purificação , Fatores de Virulência de Bordetella/análise , Fatores de Virulência de Bordetella/genética , Coqueluche/prevenção & controle , Sequência de Aminoácidos , Sequência de Bases , Bordetella pertussis/genética , Criança , Pré-Escolar , Análise por Conglomerados , Doenças Transmissíveis Emergentes/genética , DNA Bacteriano/genética , Europa (Continente) , Feminino , Genótipo , Humanos , Lactente , Masculino , Tipagem Molecular , Reação em Cadeia da Polimerase , Polimorfismo de Nucleotídeo Único , Análise de Sequência de DNA , Coqueluche/epidemiologia , Coqueluche/microbiologiaRESUMO
A double blind placebo-controlled efficacy trial of two acellular pertussis vaccines was conducted in 3801 6- to 11-month-old children. Four vaccinated children died during 7 to 9 months follow-up as a result of Haemophilus influenzae type b meningitis, heroin intoxication with concomitant pneumonia, suspected septicemia, and Neisseria meningitidis Group B septicemia. From the actual death rate in children belonging to the same birth cohort in Sweden that could have been eligible for the trial, one death was expected among vaccinated children. Several investigations were carried out to examine the possibility that the deaths could be causally related to the vaccination. The relative risk for hospitalization due to systemic or respiratory infections was 1.07 (95% confidence interval, 0.95 to 1.20) and 0.83 (95% confidence interval, 0.64 to 1.08) in the vaccine groups as compared with the placebo group. Subsets of the population were studied for signs of immunosuppression. There was no indication of immunoglobulin deficiency or any sign of clinically significant leukopenia or lymphocytosis in vaccine recipients. The results of this analysis provide no evidence for a causal relation between vaccination with the studied acellular pertussis vaccines and altered resistance to invasive disease caused by encapsulated bacteria. The hypothesis that the two variables are related, however, cannot be refuted from these data.
Assuntos
Infecções Bacterianas/prevenção & controle , Vacina contra Coqueluche , Toxoides , Anticorpos Antibacterianos/análise , Infecções Bacterianas/imunologia , Infecções Bacterianas/mortalidade , Ensaios Clínicos como Assunto , Método Duplo-Cego , Feminino , Humanos , Lactente , Masculino , SuéciaRESUMO
During a placebo controlled trial of acellular pertussis vaccines a cluster of invasive bacterial infections with fatal outcome occurred among vaccinated children as compared with unvaccinated Swedish children of the same birth cohort (4). Clinical and immunological studies did not support the hypothesis of an immunosuppressive effect of the vaccines, which would explain the deaths, but the hypothesis could not be refuted by the data. To evaluate the safety of acellular pertussis vaccines regarding rare severe events--in particular invasive infectious diseases--prospective studies seem to be needed, comparing very large groups. A coordinated and controlled vaccine programme during 1-2 years in most of Sweden combined with national reports of invasive infections may serve as a basis for such a study. A possible study design is given below.
Assuntos
Infecções Bacterianas/etiologia , Vacina contra Coqueluche/efeitos adversos , Infecções Bacterianas/epidemiologia , Infecções Bacterianas/mortalidade , Ensaios Clínicos como Assunto , Humanos , Lactente , Vacina contra Coqueluche/isolamento & purificação , Fatores de Risco , Suécia/epidemiologiaRESUMO
BACKGROUND: From October 2009 to January 2010, approximately 470,000 children and adolescents in Norway ages 4-19 years were vaccinated with Pandemrix® against influenza A (H1N1 subtype). The vaccination coverage in this age cohort was approximately 50%. OBJECTIVES: Our study was performed to evaluate the possible association between Pandemrix® vaccination and narcolepsy in Norway. METHODS: Children and adolescents with sudden onset of excessive daytime sleepiness (EDS) and cataplexy occurring after the 2009-2010 vaccination period were registered by the National Institute of Public Health in cooperation with the Norwegian Resource Center for AD/HD, Tourette Syndrome, and Narcolepsy. RESULTS: Fifty-eight vaccinated children and adolescents (35 girls, 23 boys) ages 4-19 years (mean age, 10.5 years) were diagnosed as new cases of confirmed narcolepsy and were included in our study during 2010 and 2011. Forty-two children had onset of symptoms within 6 months after vaccination, with 12 of them having symptoms within the first 6 weeks. All had EDS, 46 had documented cataplexy, 47 had mean sleep latency less than 8 min, and 43 had two or more sleep-onset rapid eye movement sleep (SOREM) periods in multiple sleep latency tests (MSLT). Cerebrospinal fluid (CSF) hypocretin levels were measured in 41 patients, with low levels in all. Thirty seven patients that were analyzed had tissue type HLADQB1*0602. During the same period, 10 unvaccinated cases were reported (mean age, 12.5 years). CONCLUSION: The data collected during 3 years following vaccination showed a significantly increased risk for narcolepsy with cataplexy (P<.0001) and reduced CSF hypocretin levels in vaccinated children ages 4-19 years the first year after Pandemrix® vaccination, with a minimum incidence of 10 of 100,000 individuals per year. The second year after vaccination, the incidence was 1.1 of 100,000 individuals per year, which was not significantly different from the incidence of 0.5-1 of 100,000 per year in unvaccinated children during the same period.
Assuntos
Vírus da Influenza A Subtipo H1N1/imunologia , Vacinas contra Influenza/efeitos adversos , Influenza Humana/prevenção & controle , Narcolepsia/epidemiologia , Narcolepsia/etiologia , Adolescente , Cataplexia/líquido cefalorraquidiano , Cataplexia/epidemiologia , Cataplexia/etiologia , Criança , Pré-Escolar , Distúrbios do Sono por Sonolência Excessiva/líquido cefalorraquidiano , Distúrbios do Sono por Sonolência Excessiva/epidemiologia , Distúrbios do Sono por Sonolência Excessiva/etiologia , Feminino , Humanos , Incidência , Influenza Humana/imunologia , Peptídeos e Proteínas de Sinalização Intracelular/líquido cefalorraquidiano , Masculino , Narcolepsia/líquido cefalorraquidiano , Neuropeptídeos/líquido cefalorraquidiano , Noruega/epidemiologia , OrexinasRESUMO
Prolonged unblinded passive surveillance of the trial cohort from the Swedish 1986-87 pertussis vaccine efficacy trial indicates that a two-component vaccine, containing pertussis toxoid and filamentous haemagglutinin, provided better long-term protection against pertussis than a monocomponent pertussis toxoid vaccine. The relative risk (RR) for culture-confirmed pertussis was 1.5 (95% confidence interval (CI) 1.0-2.4), and RR for pertussis according to parents' diagnoses was also 1.5 (95% CI 1.1-2.1), for the monocomponent vaccine compared with the two-component vaccine.
Assuntos
Vacina contra Coqueluche/uso terapêutico , Coqueluche/prevenção & controle , Feminino , Humanos , Incidência , Lactente , Masculino , Fatores de Tempo , Coqueluche/epidemiologiaRESUMO
Household studies in the two recently concluded Swedish pertussis vaccine efficacy trials demonstrated that one monocomponent and one five-component candidate acellular pertussis vaccine had reasonably good protective efficacy against clinically typical pertussis after household exposure. Another recently concluded German household study, led from Mainz, also demonstrated reasonably good efficacy for a three-component acellular pertussis vaccine. The methods of case ascertainment and duration of follow-up had a marked influence on the efficacy estimates of another candidate two-component acellular pertussis vaccine. This vaccine and a U.S. licensed commercial whole-cell vaccine had very low efficacy against pertussis infection after household exposure. Differences in methodology preclude direct comparisons between the efficacy estimates obtained in various household studies.
Assuntos
Vacina contra Difteria, Tétano e Coqueluche , Coqueluche/prevenção & controle , Infecções Comunitárias Adquiridas/epidemiologia , Vacinas contra Difteria, Tétano e Coqueluche Acelular , Transmissão de Doença Infecciosa , Características da Família , Seguimentos , Alemanha/epidemiologia , Humanos , Lactente , Transmissão Vertical de Doenças Infecciosas , Vacina contra Coqueluche , Suécia/epidemiologia , Resultado do Tratamento , Coqueluche/terapiaRESUMO
During a randomized trial of a cellular pertussis vaccines, significantly fewer recipients of a two-component vaccine (Japanese National Institute of Health [JNIH]-6) were diagnosed as primary or coprimary cases in households than either placebo recipients or those who received a monocomponent pertussis toxoid vaccine (JNIH-7). After household exposure to a culture-confirmed primary case, efficacy for JNIH-6 was estimated to be 35% (95% confidence interval, -14% to 57%) against any culture-confirmed disease and 58% (95% confidence interval, -6% to 84%) against clinical disease with 21 days or more of coughing spasms. The corresponding efficacy estimates for JNIH-7 were 67% (95% confidence interval, 32% to 80%) and 82% (95% confidence interval, 41% to 96%). Differences between the JNIH-6 and JNIH-7 vaccines in efficacy after household exposure were not statistically significant. No association could be established between protection against pertussis after household exposure and serum levels of IgG antibody to pertussis toxin or filamentous hemagglutinin in vaccinated individuals, in either study children or other household members.
Assuntos
Vacina contra Coqueluche/imunologia , Coqueluche/imunologia , Coqueluche/prevenção & controle , Adolescente , Adulto , Anticorpos Antibacterianos/sangue , Criança , Pré-Escolar , Saúde da Família , Humanos , Lactente , Estudos ProspectivosRESUMO
Nasopharyngeal cultures and titer rises in paired sera were evaluated in a placebo-controlled pertussis vaccine efficacy trial. IgG ELISA for filamentous hemagglutinin (FHA) identified 30 (88%) of 34 placebo recipients and 33 (89%) of 37 vaccine recipients with culture-verified Bordetella pertussis infections, whereas IgG ELISA for pertussis toxin (PT) showed higher diagnostic sensitivity in the placebo group than in the vaccine groups. The CHO cell assay did not improve sensitivity. Children with Bordetella parapertussis infections had rises of titers of antibody to FHA of the same magnitude as children with B. pertussis infections. Sensitive serologic criteria, based on the intraassay variations, identified 105 additional culture-negative cases with significant titer rises in paired sera. IgG ELISA for FHA and PT and IgA ELISA for FHA were reliable assays, and bacterial isolation rates were lower in vaccine recipients than in placebo recipients with serologically defined pertussis.
Assuntos
Anticorpos Antibacterianos/sangue , Bordetella pertussis/isolamento & purificação , Nasofaringe/microbiologia , Vacina contra Coqueluche/imunologia , Coqueluche/diagnóstico , Bordetella pertussis/imunologia , Ensaio de Imunoadsorção Enzimática , Reações Falso-Positivas , Hemaglutininas/imunologia , Humanos , Imunoglobulina A/análise , Imunoglobulina G/análise , Lactente , Toxina Pertussis , Valor Preditivo dos Testes , Fatores de Virulência de Bordetella/imunologiaRESUMO
In an investigation of cell-mediated immunity against Bordetella pertussis, we found that B. pertussis infection in infants and in mice was associated with the induction of antigen-specific T cells that secrete IFN-g and IL-2, but not IL-4 or IL-5. This cytokine profile is characteristic of Th1 cells that mediate cellular immune responses against a range of intracellular pathogens. An examination of cytokine production following immunization with a three-component acellular vaccine, comprising inactive PT, FHA and pertactin adsorbed to alum, demonstrated that spleen cells from vaccinated mice produced high levels of IL-5, but no detectable IFN-g and low levels of IL-2. In contrast, peripheral blood mononuclear cells from vaccinated infants produced IL-2, IL-5 and IFN-g. These findings highlight significant differences in the immune responses generated by vaccination and natural infection with B. pertussis and demonstrate that the T-cell response induced with an acellular vaccine, although dominated by type 2 cytokines in mice, is more heterogeneous in infants with a Th0 or mixed Th1/Th2 cytokine profile.
Assuntos
Bordetella pertussis/imunologia , Citocinas/biossíntese , Vacina contra Difteria, Tétano e Coqueluche/imunologia , Células Th1/imunologia , Células Th2/imunologia , Coqueluche/imunologia , Adulto , Animais , Anticorpos Antibacterianos/biossíntese , Citocinas/imunologia , Citocinas/metabolismo , Vacinas contra Difteria, Tétano e Coqueluche Acelular , Humanos , Imunidade Celular , Lactente , Camundongos , Células Th1/microbiologia , Células Th2/microbiologia , Vacinação , Coqueluche/metabolismo , Coqueluche/prevenção & controleRESUMO
Vaccine efficacies against typical pertussis after household exposure to Bordetella pertussis were estimated to be 75.4% for an acellular five-component vaccine, 42.4% for an acellular two-component vaccine, and 28.5%, for a licensed US whole cell vaccine, compared to placebo. Logistic regression analyses demonstrated statistically significant correlations between clinical protection and the presence of IgG antibodies against pertactin, fimbriae 2/3 and pertussis toxin in pre-exposure sera. Multicomponent pertussis vaccines of proven high efficacy in recent Swedish NIAID-sponsored efficacy trials induced higher antibody levels against pertactin and fimbriae 2/3 than less efficacious vaccines. Anti-pertactin, anti-fimbriae 2/3, and anti-PT may be used as surrogate markers of protection for multicomponent acellular and whole-cell vaccines against pertussis.
Assuntos
Anticorpos Antibacterianos/sangue , Bordetella pertussis/imunologia , Vacina contra Difteria, Tétano e Coqueluche/imunologia , Proteínas de Fímbrias , Vacina contra Coqueluche/imunologia , Adesinas Bacterianas/imunologia , Antígenos de Bactérias/imunologia , Proteínas da Membrana Bacteriana Externa/imunologia , Proteínas de Bactérias/imunologia , Biomarcadores/sangue , Infecções Comunitárias Adquiridas , Vacinas contra Difteria, Tétano e Coqueluche Acelular , Ensaio de Imunoadsorção Enzimática , Feminino , Fímbrias Bacterianas/imunologia , Hemaglutininas/imunologia , Humanos , Imunoglobulina G/análise , Lactente , Masculino , Líquido da Lavagem Nasal/microbiologia , Nasofaringe/microbiologia , Toxina Pertussis , Resultado do Tratamento , Fatores de Virulência de Bordetella/imunologia , Coqueluche/imunologia , Coqueluche/prevenção & controle , Coqueluche/transmissãoRESUMO
A placebo-controlled efficacy trial of two acellular pertussis vaccines carried out in Sweden in 1986-87 used culture confirmation as the principal case definition. However, the sensitivity of pertussis culture is low, and secondary analyses using more sensitive serological diagnostic criteria have therefore been carried out. These analyses confirm that vaccination with pertussis toxoid alone does protect against typical whooping cough with laboratory confirmation, but show that it does not protect against infection or colonization. There is evidence that the addition of filamentous haemagglutinin provides some protection against infection. Bacterial isolation rates were lower in vaccinated than unvaccinated children with serologically confirmed pertussis and increased with disease severity.
Assuntos
Vacina contra Coqueluche/uso terapêutico , Toxoides/uso terapêutico , Vacinação , Coqueluche/prevenção & controle , Criança , Pré-Escolar , Ensaio de Imunoadsorção Enzimática , Humanos , Placebos , Suécia , Coqueluche/imunologiaRESUMO
The efficacy of two acellular pertussis vaccines was estimated for various clinical case definitions, with and without the requirement of culture confirmation, from a randomized trial in Sweden. Efficacy increased with duration of coughing spasms and when the case definition included whoops or whoops plus at least nine coughing spasms a day. After deletion of clinical cases not believed to be caused by pertussis, efficacies were closer to the higher values for culture-confirmed disease. Nonspecificity of the clinical criterion "21 days of coughing spasms with whoops" resulted in estimates of predictive value for pertussis of 85% for placebo recipients and 56% for vaccinees. We conclude that laboratory confirmation of suspected cases is needed in pertussis vaccine trials. A suggested case definition is 21 days or more of coughing spasms with confirmation by culture, serologic study, or household exposure to culture-confirmed pertussis.
Assuntos
Imunoterapia/normas , Vacina contra Coqueluche/uso terapêutico , Coqueluche/diagnóstico , Humanos , Lactente , Projetos de Pesquisa/normas , Fatores de Risco , Sensibilidade e Especificidade , Suécia/epidemiologia , Coqueluche/epidemiologia , Coqueluche/prevenção & controleRESUMO
The mechanism of protective immunity against Bordetella pertussis generated following recovery from whooping cough in childhood has not yet been elucidated. Studies with a murine respiratory infection model have indicated that cellular immunity, mediated by Th1 cells, plays a role in the clearance of a primary infection with B. pertussis and in protection against subsequent challenge. In the present study, the induction of B. pertussis-specific Th cell subsets in children was examined. Peripheral blood mononuclear cells from B. pertussis-infected or convalescent children proliferated and secreted cytokines following antigen stimulation in vitro. In contrast, responses were weak or undetectable in the majority of children who had not been infected or vaccinated. In all cases, responding T cells produced interferon-gamma but low or undetectable interleukin-5. The findings suggest that Th1 cells may play a role in protective immunity generated following infection with B. pertussis in children.
Assuntos
Bordetella pertussis/imunologia , Citocinas/biossíntese , Ativação Linfocitária , Células Th1/imunologia , Coqueluche/imunologia , Envelhecimento , Células Cultivadas , Criança , Pré-Escolar , Convalescença , Humanos , Lactente , Interferon gama/biossíntese , Interleucina-4/biossíntese , Interleucina-5/biossíntese , Subpopulações de Linfócitos T/imunologia , Fatores de Tempo , Coqueluche/sangueRESUMO
Studies on serologic correlates to protection in pertussis were reviewed. Trials in the 1950s showed that agglutinogen titers correlated to protection of whole-cell vaccines, but postvaccination antibodies against pertussis toxin (PT) and against filamentous hemagglutinin did not in a later trial of acellular vaccines. However, in household studies nested in 2 recent trials, preexposure antibody levels against pertactin and against fimbriae correlated with protection against typical and mild pertussis, and anti-PT correlated only with protection against typical pertussis. These findings could be used by regulatory agencies to license pertussis vaccines. A reference laboratory for pertussis should distribute panels to control interlaboratory variation in recommended assays, and a minimal response should be set for each pertussis antigen. We conclude that 2 studies have shown correlates between measurable anti-pertactin, anti-fimbriae, and anti-PT antibody levels at exposure and individual protection against pertussis. We suggest that postvaccination response rates may be used as surrogate markers of protection.
Assuntos
Vacina contra Coqueluche/imunologia , Coqueluche/prevenção & controle , Anticorpos Antibacterianos/sangue , Antígenos de Bactérias/imunologia , Proteínas da Membrana Bacteriana Externa/imunologia , Biomarcadores/sangue , Estudos de Casos e Controles , Ensaios Clínicos como Assunto , Fímbrias Bacterianas/imunologia , Humanos , Toxina Pertussis , Padrões de Referência , Fatores de Virulência de Bordetella/imunologia , Coqueluche/imunologiaRESUMO
Data from two Swedish pertussis vaccine trials with various combination vaccines were used to compare anti-diphtheria antitoxin concentrations over time between different vaccines, vaccine lots and vaccine schedules. The immune responses were measured with a validated ELISA method.Results are given for 1326 children, born 1992, that were recruited to the placebo (DT)-controlled Trial I which used a 2, 4, 6 month schedule. Two DTP acellular and one DTP whole cell vaccine were used. No DT boosters were given until 5 years of age. Trial II recruited children born 1993-94 and compared three DTP acellular vaccines with one DTP whole cell vaccine. Results are given for 306 children in a 2, 4, 6 month schedule and for 531 children in a 3, 5, 12 month schedule. The latter schedule gave significantly higher diphtheria antitoxin concentrations post third dose. The various DTP acellular vaccines and an inefficacious DTP whole cell vaccine gave lower antitoxin concentrations than both an efficacious DTP whole cell vaccine and the DT vaccine. The larger differences in antigen response between vaccines was reduced in the course of time. Generally, an initial rapid decline of antitoxin concentration was followed by a slower decline; the change typically occurring when the antitoxin concentration reached 0.13-0.16 EU/ml. The time needed to reach this level was between 6 and 10 months based on the initial vaccine response.A "best-fit" combined exponential regression model was used to predict the optimal timing for booster vaccinations against diphtheria.Our data support a 3, 5, 12 month schedule followed by a fourth dose 4-5 years after the third dose, depending upon the vaccine used.